In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target ...

AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing ...

Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

A whistleblower accusing Allergan Inc. of engaging in a kickback scheme to increase purchases of “Lap-Band’ obesity devices can advance a portion of his suit toward trial, a Maryland federal judge ...

Image credit: Skorzewiak / Shutterstock AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for ...

the BMO note indicates that AbbVie still “expects emraclidine opportunity to remain.” The company is planning to test higher doses of the drug. Gilead Fends Off Criticism for Lenacapavir Access ...

According to the company, Walmart's updated logo is inspired by his trucker hat. (Luke Frazza/AFP/Getty Images) According to Business Insider, Walmart has rolled out seven different logos prior ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. AbbVie leaders are “disappointed” with poor ...

AbbVie returned to modest growth in 2024 and 2025 figures to be a return to “robust growth," according to the CEO. Through 2029, the company envisions sales will grow in the high-single-digit ...

Wells Fargo & Company increased their price objective on shares of AbbVie to $195.00 and gave the company a “buy” rating in a research report on Tuesday, November 19th.

Last week, AbbVie said that it would record a charge of about $3.5 billion related to the drug. The company is looking to compete with Bristol Myers Squibb's (BMY.N), opens new tab Cobenfy ...